* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXXF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Pharmala Biotech Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmala Biotech Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharmala Biotech Holdings's Days Payable falls into.
Pharmala Biotech Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharmala Biotech Holdings's Days Payable for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmala Biotech Holdings (MDXXF) has a Days Payable of 0.00 as of Feb. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmala Biotech Holdings and its competitors. Over the past decade, Pharmala Biotech Holdings' Days Payable has ranged from 828.65 to 2,493.02. According to the industry distribution chart, Pharmala Biotech Holdings ranks #81 out of 701 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Pharmala Biotech Holdings' Days Payable too high?
Pharmala Biotech Holdings' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 828.65 to a high of 2,493.02. Based on the distribution chart, Pharmala Biotech Holdings ranks #81 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmala Biotech Holdings ranks #81 out of 701 companies for Days Payable. This places Pharmala Biotech Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Pharmala Biotech Holdings' own Days Payable has ranged from 828.65 to 2,493.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmala Biotech Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmala Biotech Holdings's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current Days Payable is 0.00. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Days Payable is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued.
The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15.
GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.
Key valuation signals for MDXXF:
Days Payable: 0.00
GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score
Get the complete analysis for MDXXF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXXF has been successfully added to your 
